| Presentation preference | Oral presentation |
| Title | A small case series of the development of uveitis in dupilumab-treated atopic dermatitis patients |
| Purpose | Conjunctivitis is the most frequently reported side effect during dupilumab treatment in moderate-to-severe atopic dermatitis (AD) patients. Nevertheless, other ophthalmic adverse events in dupilumab-treated AD patients have been reported in literature, but only few data is available. Here, we report a case series of six moderate-to-severe AD patients who developed uveitis during dupilumab treatment. |
| Methods | Included AD patients developed uveitis after starting dupilumab treatment and were seen at the University Medical Center Utrecht, the Netherlands. |
| Results | Six patients developed uveitis within 2 weeks to 24 months after starting dupilumab. The underlying causes of uveitis were HLA B 27 ankylosing spondylitis, undiagnosed sarcoidosis, VKH syndrome, and unknown origin (n=3) complicated by macular edema in one and secondary glaucoma in another case. There seems to be a predisposing factor for development of uveitis in the first three cases, whereas one patient with uveitis of unknown origin suffered from cutaneous lupus. |
| Conclusion | On the basis of this small case series, we conclude that uveitis can occur as a rare adverse event of dupilumab treatment in AD patients, probably with pre-existent risk factors for developing uveitis. |
| Conflict of interest | No |
Authors 1
| Last name | VAN LUIJK |
| Initials of first name(s) | CM |
| Department | Ophthalmology |
| City | Utrecht |
| Country | Netherlands |
Authors 2
| Last name | Achten |
| Initials of first name(s) | R |
| Department | Dermatology |
| City | Utrecht |
| Country | Netherlands |
Authors 3
| Last name | de Bruin-Weller |
| Initials of first name(s) | M |
| Department | Dermatology |
| City | Utrecht |
| Country | Netherlands |
Authors 4
| Last name | de Boer |
| Initials of first name(s) | J |
| Department | Ophthalmology |
| City | Utrecht |
| Country | Netherlands |
